Progen encouraged by pilot trial results
17 May, 2005 by Graeme O'NeillA Phase IIa pilot trial of its promising PI-88 angiogenesis inhibitor in patients with advanced melanoma has convinced Brisbane cancer-drug developer Progen Industries (ASX: PGL, NASDAQ: PGLAF) to move its lead compound into a Phase IIb trial.
Eiffel looking to cut costs
16 May, 2005 by Ruth BeranDrug re-engineering company Eiffel (ASX:EIF) has issued shares worth a total of $70,000 as part of the cancellation of an employee contract, and is looking to cut costs.
Avastra trial delayed
16 May, 2005 by Ruth BeranThe clinical trial being run by Sydney biomaterials company Avastra (ASX:AVS) for its BioWeld device has been delayed by six months due to severe post-operative complications experienced by the first patient.
ARRM opts for voluntary receivership
16 May, 2005 by Staff WritersSources close to Adelaide-based Advanced Rapid Robotic Manufacturing have revealed that the company has gone into voluntary receivership.
Select Vaccines licenses hepatitis E antibodies
13 May, 2005 by Graeme O'NeillMelbourne's Select Vaccines (ASX:SLT) announced today it has licensed serologicals company Upstate USA to market and distribute Select's five proprietary monoclonal antibodies to hepatitis E virus for research purposes.
New tax relief could lure foreign biotech CEOs here
13 May, 2005 by Graeme O'NeillThis week's federal budget contained a taxation measure designed to prime a 'brain siphon' that could help Australian biotechnology companies recruit experienced CEOs and other experienced senior executives from the US, Britain and Europe.
Aussie to test spirulina in microgravity flight
11 May, 2005 by Graeme O'NeillA researcher from the Australian National University is about to take a flight in microgravity, to see whether the protein-rich blue-green alga Spirulina platensis is the Right Stuff as food for space travel.
Novogen claims four-leaf result from cancer drug trial
11 May, 2005 by Graeme O'NeillSydney oncology drug developer Novogen (ASX:NRT, NASDAQ:NVGN) can smell the clover across the width of the Pacific, after its Connecticut-based subsidiary Marshall Edwards (LSE AIM:MSH and NASDAQ:MSHL) reported outstanding preliminary results from a trial of its clover-derived cancer drug phenoxodiol.
Prima Biomed and pSivida granted patents
10 May, 2005 by Ruth BeranMelbourne-based biotech Prima Biomed (ASX:PRR) has been granted a patent by the European Patent Office for its CancerVac therapy, and nanotechnology company pSivida (ASX:PSD, NASDAQ:PSDV, Xetra:PSI) has been granted its first Chinese patent.
New CEO for expanding PharmAust
09 May, 2005 by Ruth BeranDr John Moursounidis has been hired as CEO for West Australian pharmaceutical company PharmAust (ASX:PAA).
New brief for Monash health economics centre
09 May, 2005 by Ruth BeranMonash University's Centre for Health Economics has moved to new premises in the Science Technology and Innovation Precinct at Monash University's Clayton campus, and will be looking at setting up partnerships with industry for the first time.
First Sunshine Heart device implanted
09 May, 2005 by Ruth BeranDoctors at Auckland City Hospital have conducted the first long-term implant of a Sunshine Heart (ASX:SHC) C-Pulse heart device in a 56-year old New Zealand man.
IMB ploughs Xenome profit back into science commercialisation
06 May, 2005 by Ruth BeranThe University of Queensland's multi-million dollar exit from unlisted Brisbane biotech Xenome has led to the establishment of a new $750,000 proof-of-concept fund for reinvestment in commercially viable research projects at UQ's Institute for Molecular Bioscience.
Peptech announces profit upgrade, denies merger rumours
06 May, 2005 by Ruth BeranDespite a strong cash position of AUD$44.8 million, boosted by an interim net profit after tax of $23.9 million for the half-year ended 31 March 2005, Sydney biotech Peptech (ASX:PTD) has said it is "not actively participating in the M&A space" at the moment, and denied renewed speculation of a merger with Melbourne's Amrad (ASX:AMD).
BRC lands Glaxo contract
05 May, 2005 by Ruth BeranGlaxoSmithKline Research and Development is to buy two Brain Resource Laboratories from Sydney-based brain function databasecompiler Brain Resource Company (ASX:BRC), for operation at Quintiles' Guys Drug Research Unit in London.
